Advertisement

Why Longeveron Stock Skyrockted 661.2% in November

Why Longeveron Stock Skyrockted 661.2% in November

Shares of Longeveron (NASDAQ: LGVN) jumped 661.2% in November, according to data from S&P Global Market Intelligence. The stock surged after it was announced that the company received a Rare Pediatric Disease (RPD) designation for its Lomecel-B treatment. Longeveron announced on Nov. 18 that Lomecel-B had received RPD designation for the treatment of hypoplastic left heart syndrome (HLHS) -- a potentially fatally heart condition in infants.